Title of article
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Author/Authors
Daniel J. Drucker، نويسنده , , John B Buse، نويسنده , , Kristin Taylor، نويسنده , , David A. Kendall، نويسنده , , Michael Trautmann، نويسنده , , Dongliang Zhuang، نويسنده , , Lisa Porter، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2008
Pages
11
From page
1240
To page
1250
Abstract
Summary
Background
Exenatide is an incretin mimetic that shares glucoregulatory properties with glucagon-like peptide 1 (GLP-1), and improves glycaemic control, with progressive bodyweight reductions, when administered twice a day in patients with type 2
Journal title
The Lancet
Serial Year
2008
Journal title
The Lancet
Record number
593548
Link To Document